Adults with mild cognitive impairment and sleep disturbances who took at least 5,000 IU of vitamin D daily scored more than 13% higher on a standard cognitive test than those taking none — a preliminary finding from a 54-person study that its own authors describe as hypothesis-generating rather than conclusive.
With more than 7 million Americans currently living with Alzheimer’s dementia — a figure projected to approach 13 million by 2050 — researchers continue to search for modifiable factors that could delay or reduce cognitive decline in people at elevated risk. New research from Emory University, published in the journal Sleep Medicine, examined one such candidate: vitamin D supplementation.
The study followed 54 adults who had both mild cognitive impairment (MCI) — an intermediate stage between normal age-related cognitive change and dementia — and sleep disturbances, a combination associated with elevated dementia risk. Participants who reported taking 5,000 IU or more of vitamin D daily scored more than 13% higher on the Montreal Cognitive Assessment (MoCA), a widely used screening test for memory and thinking skills, compared with participants taking no vitamin D supplement, even after researchers adjusted for other contributing factors. Notably, lower daily doses of vitamin D showed no such association, and cognitive scores did not differ meaningfully between the two common forms of the vitamin, D2 and D3.
Why the caveats matter here
This is an observational study of self-reported supplement intake, not a randomised controlled trial in which researchers assigned participants to take vitamin D or a placebo. That distinction matters: an association between higher vitamin D intake and better cognitive scores does not establish that the vitamin caused the improvement — people who choose to take higher-dose supplements may differ from those who do not in other health-relevant ways that the study’s statistical adjustments may not fully capture. The sample size, 54 participants, is small by the standards needed to draw confident population-level conclusions, and the finding awaits replication in a larger, ideally randomised, study before it could inform clinical guidance. The researchers themselves frame the results as identifying vitamin D as “a potentially modifiable factor” worth further study during an early window of cognitive decline — measured, hypothesis-generating language rather than a claim of clinical benefit.
Why it matters
Vitamin D deficiency is common, inexpensive to correct, and supplementation carries a well-established safety profile at typical doses, which makes it an attractive candidate for further dementia-prevention research even from a small preliminary study — the practical bar for testing a low-cost, low-risk intervention further is lower than for a novel pharmaceutical. If a larger trial confirms the association and, more importantly, establishes that supplementation actually improves outcomes rather than merely correlating with them, it could represent an unusually accessible intervention for a population at high dementia risk. For now, however, this remains one modest study awaiting confirmation, and readers experiencing cognitive changes or considering high-dose supplementation should treat it as exactly that rather than as established guidance, and discuss any supplementation decisions with a physician given that very high vitamin D doses over sustained periods can carry their own risks.
-Kalyan S Maramaganti
Key facts
– Study of 54 adults with mild cognitive impairment and sleep disturbances; observational, not a randomised controlled trial
– Participants taking ≥5,000 IU vitamin D daily scored >13% higher on the Montreal Cognitive Assessment than those taking none
– Lower doses showed no association; no difference between vitamin D2 and D3 forms
– Published in Sleep Medicine; research from Emory University
